|
市場調查報告書
醫學聯絡（MSL）的評價基準
MSL Metrics: Measuring Success
|
醫學聯絡（MSL）的評價基準 是由出版商Doctor's Guide Publishing Limited (FirstWord Pharma)在2011年12月所出版的。
這份英文市場調查報告書包含26 Pages 價格從美金595起跳。
醫學聯絡（MSL）難以用數値評價、其作用也不斷變化、定義也不好分類，另一方面、對製藥產業來說是擁有付加價値的作用是無庸置疑的事實。
本報告書為MSL作用的發展與研究者、保險公司、政府間的關係相關的考察、與KOL的關係、MSL分類的特殊化之相關讚否意見等、概述如下。
第1章 總綱
第2章 MSL與業務人員的差異
- 企業的耳與目
- 多樣化的作用
- 為了與KOL接觸而讓競爭激化
- 不適當的評價方法
第3章 MSL業績評價
- 數値
- 數量
- 質
- 量化的計測
- 滿足企業內的利害關係者
- 持續調整
- 數字感覺
第4章 MSL配置
- 特殊化領域
- 臨床實驗的MSL
- 保險公司
- 政府
- 特殊化與柔軟性
- 治療中的特殊化是必要的嗎
- KOL分類
- 從好的部分中除掉不好的
- 調整測定基準
第5章 MSL計畫
- 案例研究
- 構成要素
- 必要的數據
- 開發計畫
- 訪問頻度
- 多樣性
- 生產計畫
- 反應型作業
- 變化的企業需求
- 評分卡
第6章 MSL視點
第7章 確認事項
第3章 總綱
第4章 由KOL所見的現在順利運作的點
第5章 由KOL所見的現在無法順利運作的點
第6章 KOL與製藥公司關係間存在著的未滿足的需求
- KOL想從變化的製藥公司得到的經驗
- KOL沒想到能從變化的製藥公司得到的經驗
第7章 實現與製藥公司的理想關係之要因
第8章 孕育將來性KOL與產業關係的重點
第9章 KOL略歴
Abstract
It's difficult to quantify. Its role constantly changes. And despite all
efforts to gain transparency, the field of medical science liaison (MSL)
remains an elusive - seemingly immeasurable - yet undeniable value-added role
in the pharmaceutical industry.
In this latest report, FirstWord Dossier tackles the intangible nature of MSL
work to describe not only the obstacles to identifying appropriate,
attributable and transparent metrics, but how to develop them so that they
align with corporate objectives.
Overview
While contributing significantly to company success, quantifying what MSLs do
has always proven elusive. In MSL Metrics: Measuring Success, FirstWord
unravels the subtle impact of the MSL field force. The report reviews the main
quantitative and qualitative metrics used to measure achievement, offers
insight into how MSLs specialise - and the drawbacks that may represent - and
examines the structure of successful MSL programmes. Concisely written, the
report offers the industry clear-sighted, practical strategies for creating a
solid approach to measuring MSL success.
Key Report Features
- Discussion of the evolution of the MSL role and their relationships with
researchers, payers and government
- Feedback from KOLs on what they want from MSLs
- Discussion of generic versus targeted metrics
- Data on the main quantitative and qualitative metrics used by industry
- The pros and cons of MSL field force specialisation
- How to align MSL metrics with corporate and medical affairs objectives
Key Benefits
- Expert insight from key players in medical affairs on the most appropriate
and effective metrics
- Practical tips for measuring quantitative and qualitative results
- Access to the MSL perspective, case studies and building effective MSL
programmes
Who Would Benefit From This Report?
- Medical and scientific affairs managers
- Global medical affairs managers
- Sales and marketing managers
- Professional and medical science liaison officers
- Key account and territory managers
- Communications and technology support teams
- Health outcomes managers
Expert Views
- Jane Chin, founder of the MSL Institute and managing partner of
9Pillars
- Eric Kassel, senior scientific medical director, Allergan
- Andrew Lam, senior MSL, Shire Human Genetic Therapies
- Doral Fredericks, head of medical affairs, ISTA Pharmaceuticals
- Ashok Bhaseen, head of sales and marketing, PediaPharm
- Dr. Robin Winter-Sperry, president and CEO, Scientific Advantage
- Cameron Tew, director, Best Practices LLC
- Drew Macgregor, medical operations manager, Bristol-Myers Squibb
Europe
- Vice-president of Medical and Scientific Affairs, Company A
Table of Contents
- MSLs are not sales reps
- Eyes and ears of the company
- A diversifying role
- Increased competition to engage with KOLs
- Inadequate metrification
- Measuring MSL success
- Counting numbers
- Quantitative metrics
- Qualitative metrics
- The language of numbers
- Satisfying internal stakeholders
- Constant adjustments
- Making sense of the numbers
- How MSLs are deployed
- Areas of specialisation
- MSLs in clinical research
- Engaging payers
- Government affairs
- Specialisation versus flexibility
- Is therapeutic specialisation necessary?
- Segmenting KOLs
- Weeding out the good from the bad
- Tailoring the metrics
- MSL programmes
- Case study: Showing internal value
- Building blocks
- What data needs to be captured?
- Development plans
- Frequency of visits
- Versatility
- Capacity planning
- Reactive work
- Changing company needs
- The scorecard
- The MSL perspective
- Career progression
- Scientific voice of a company
|
